Harbour BioMed (Guangzhou) Co. Ltd.
Quick facts
Phase 3 pipeline
- HBM9036 0.25% Ophthalmic Solution · Ophthalmology
HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye. - HBM9161 Injection (680mg) · Oncology
HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Harbour BioMed (Guangzhou) Co. Ltd. portfolio CI brief
- Harbour BioMed (Guangzhou) Co. Ltd. pipeline updates RSS
Frequently asked questions about Harbour BioMed (Guangzhou) Co. Ltd.
What is Harbour BioMed (Guangzhou) Co. Ltd.'s pipeline?
Harbour BioMed (Guangzhou) Co. Ltd. has 2 drugs in Phase 3, 2 in Phase 2, 3 in Phase 1. Late-stage candidates include HBM9036 0.25% Ophthalmic Solution, HBM9161 Injection (680mg).
Related
- Sector hub: All tracked pharma companies